Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellectis Bioresearch, a specialist in genome customisation and a subsidiary of Cellectis, has released a scientific study which showed that the company's technology using cellular Genome Positioning System, or cGPS, in CHO-K1 cells, to be efficient in deriving cell-based assays for high throughput screening (HTS) studies than classical methods.
Subscribe to our email newsletter
Cellectis Bioresearch said that the new method, based on meganuclease-driven targeted integration, for the generation of stable cell lines, is compatible with HTS.
Cellectis said that the development of cell-based assays for HTS approaches is important to screen molecules on pharmaceutical targets and often requires the generation of stable cell lines. However, these cell lines are essentially created by random integration of a gene of interest (GOI) with no control over the level and stability of gene expression.
In the study, scientists from the Servier Research institute used Cellectis bioresearch’s cGPS, in CHO-K1 cells, to accomplish targeted integration of different GOIs. Five different GOIs representing 3 major drug target classes were stably integrated at the same locus in cGPS CHO-K1 cells.
Characterisation of the targeted clones revealed that the cGPS CHO-K1 system was more rapid (2-week protocol), efficient (all selected clones expressed the GOI), reproducible (GOI expression level variation of 12% maximum), and stable over time (no change in GOI expression after 23 weeks of culture) than classical random integration.
Jean Boutin, director of the molecular and cellular pharmacology division of the Servier Research Institute, said: “Achieving a physiological level of expression compatible with the relevant functional assay is important in testing pharmaceutical targets.
“We found that proteins expressed in the cGPS CHO-K1 cells are biologically active and have enzymatic constants, localisation and function close to the published values of their wild-type endogenous counterparts. This method opens the door for creating large collections of cell lines expressing therapeutically relevant GOIs, enhancing the productivity of HTS.”